Rachel McMinn - Mar 13, 2024 Form 4 Insider Report for Neurogene Inc. (NGNE)

Role
Chief Executive Officer, Director
Signature
/s/ Christine Mikail, as attorney-in-fact for Rachel McMinn
Stock symbol
NGNE
Transactions as of
Mar 13, 2024
Transactions value $
$0
Form type
4
Date filed
3/14/2024, 08:54 PM
Previous filing
Dec 26, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGNE Employee Stock Option (Right to buy) Award $0 +93.3K $0.00 93.3K Mar 13, 2024 Common Stock 93.3K $36.06 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 1/4 of the total number of shares on March 13, 2025, and then 1/48 of the total number of shares will vest monthly thereafter, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.